Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
168.18
+0.25 (0.15%)
At close: Nov 20, 2025, 4:00 PM EST
169.79
+1.61 (0.96%)
Pre-market: Nov 21, 2025, 8:26 AM EST
Biogen Revenue
Biogen had revenue of $2.53B in the quarter ending September 30, 2025, with 2.79% growth. This brings the company's revenue in the last twelve months to $10.07B, up 4.77% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.07B
Revenue Growth
+4.77%
P/S Ratio
2.44
Revenue / Employee
$1,323,590
Employees
7,605
Market Cap
24.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BIIB News
- 1 day ago - Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference - GlobeNewsWire
- 3 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 4 days ago - Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - GlobeNewsWire
- 4 days ago - Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
- 4 days ago - High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy - GlobeNewsWire
- 6 days ago - Biogen Completes Acquisition of Alcyone Therapeutics - GlobeNewsWire
- 7 days ago - Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript - Seeking Alpha
- 7 days ago - “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom - GlobeNewsWire